The drug is being developed by the Chinese biotech Abbisko Therapeutics Co. Merck KGaA holds commercial license for Pimicotinib in Chinese mainland, Hong Kong, Macau, and Taiwan, it said.

Patient centricity is a priority for Merck and its Executive Vice President and Head of EMEA Region for Merck Biopharma Global Commercial Operations, Chris Round, outlines what practical steps the ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the ...

Merck & Co said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's distributor there reduces inventories amid low demand, and the U.S. drugmaker's ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Merck, a leading science and technology company, today announced a € 70 million expansion of its ADC manufacturing ...

Shares in Merck & Co were more than 2% lower as New York trading entered its latter half on Thursday. The US pharma giant ...

with very low rates of discontinuation due to treatment-related adverse events Pimicotinib is being developed by Abbisko Therapeutics Co., Ltd.; Merck holds commercial license for pimicotinib in ...

Merck & Co., Inc.'s Q3 earnings report is anticipated on 31st October — next Thursday. Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key ...